Business
Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that multiple abstracts
About this update from Veracyte, Inc.
[{"type":"text","content":" SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that multiple abstracts will be presented at the 40th Annual European Association of Urology Congress (EAU25) demonstrating the clinical performance and utility of its Decipher tests in prostate and bladder cancer. Additionally, independent performance data supporting the company’s minimal residual disease (MRD) testing platform for muscle-invasive bladder cancer will be unveiled from a large, multicenter trial. The EAU25 meeting is taking place March 21-24 at IFEMA Madrid in Spain.\n\n“These new data reinforce the impact our Decipher tests are having on patient care in prostate and bladder cancers and how our whole-transcriptome approach is enabling us to partner with researchers to fuel new insights into the underlying biology of these diseases,” said Philip Febbo, M.D., Veracyte’s chief scientific officer and chief medical officer. “We are similarly deploying a whole-genome approach with our MRD testing platform and are excited to see data from the TOMBOLA trial at EAU25 that reinforce the strong performance of our MRD platform for muscle-invasive bladder cancer. We plan to launch a test for this indication next year.”\n\nThe following Decipher- and MRD-focused abstracts will be presented at EAU25:\n\n\nPROSTATE CANCER:\n\n\n\n\n\n \n\n\n\n\n\nTitle:\n\n\n\n\nTranscriptomic profiling of the tumor immune microenvironment reveals prognostic markers in mCRPC patients treated with LuPSMA therapy\n\n\n\n\n\nPresenter:\n\n\n\n\nAnalena Handke, M.D., Ruhr University Bochum, Bochum, Germany\n\n\n\n\n\nFormat:\n\n\n\n\nPoster (#P195)\n\n\n\n\n\nDate/Time:\n\n\n\n\nSaturday, March 22, 11:30-12:00 CET\n\n\n\n\n\nLocation:\n\n\n\n\nGreen Area, EGPT 2\n\n\n\n\n\n\n\n \n\n\n\n\n\nTitle:\n\n\n\n\nTranscriptomic expression patterns in very high risk Decipher >0.85\n\n\n\n\n\nPresenter:\n\n\n\n\nNicole Handa, M.D., Northwestern University, Chicago, Ill.\n\n\n\n\n\nFormat:\n\n\n\n\nOral (#A0587)\n\n\n\n\n\nDate/Time:\n\n\n\n\nSunday, March 23, 15:30-16:10 CET\n\n\n\n\n\nLocation:\n\n\n\n\nPurple Area, Room 1\n\n\n\n\n\n\n\n \n\n\n\n\nBLADDER CANCER:\n\n\n\n\n\n \n\n\n\n\n\nTitle:\n\n\n\n\nDiscrepancy between clinical and pathological stage after radical cystectomy: Results from a nation-wide prospective cohort...